HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Plan B Decision Expected In Coming Weeks – Barr CEO

This article was originally published in The Tan Sheet

Executive Summary

Barr Labs anticipates OTC approval of its Plan B emergency contraceptive "in the following weeks," according to CEO Bruce Downey

You may also be interested in...

No Plan B Switch Parade As User Fee Deadline Comes And Goes

FDA will deliver a decision in the "near future" on whether the Plan B emergency contraceptive pill is "approvable" for over-the-counter use in women age 16 and up, according to manufacturer Barr Labs

Plan B Switch Decision Deadline Postponed To May

An FDA decision on the Rx-to-OTC switch of emergency contraceptive Plan B (levonorgestrel .75 mg) has been pushed back from February 20 to May 20

People In Brief

Perrigo promotes in pricing, planning


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts